Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Steffen Böhm; Nhu Le; Michelle Lockley; Elly Brockbank; Asma Faruqi; Ian Said; Arjun Jeyarajah; Rekha Wuntakal; Blake Gilks; Naveena Singh

doi:10.1136/ijgc-2018-000092

Article info

Original Article

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Authors

Steffen Böhm Department of Medical Oncology, Barts Health NHS Trust, London, UK PubMed articles Google scholar articles
Nhu Le Cancer Epidemiology and Prevention, British Columbia Cancer Agency, Vancouver, British Columbia, Canada PubMed articles Google scholar articles
Michelle Lockley Barts Cancer Institute, Queen Mary University of London, London, UK PubMed articles Google scholar articles
Elly Brockbank Department of Gynaecologial Oncology, Barts Health NHS Trust, London, UK PubMed articles Google scholar articles
Asma Faruqi Department of Pathology, Barts Health NHS Trust, London, UK PubMed articles Google scholar articles
Ian Said Department of Pathology, Barts Health NHS Trust, London, UK Department of Histopathology, Mater Dei Hospital, Msida, Malta PubMed articles Google scholar articles
Arjun Jeyarajah Department of Gynaecologial Oncology, Barts Health NHS Trust, London, UK PubMed articles Google scholar articles
Rekha Wuntakal Department of Gynaecological Oncology, Queens Hospital, Romford, UK PubMed articles Google scholar articles
Blake Gilks Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada PubMed articles Google scholar articles
Naveena Singh Department of Pathology, Barts Health NHS Trust, London, UK PubMed articles Google scholar articles

Correspondence to Steffen Böhm, Medical Oncology, Barts Health NHS Trust, London EC1A 7BE, UK; bohm.st{at}hotmail.com

View Full Text

Citation

Böhm S, Le N, Lockley M, et al

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

International Journal of Gynecologic Cancer 2019;29:353-356.

Publication history

Received October 16, 2018
Revision received November 30, 2018
Accepted December 2, 2018
First published January 25, 2019.

Online issue publication

August 17, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password